DerekSJ_a1c said:No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.
Can confirm. Same sequence, different timescale. Nothing to add that would improve it.
DerekSJ_a1c said:No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.
Coming at DerekSJ_a1c’s question from a different direction. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
The figures, for anyone assembling their own picture. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
PeptideChemSF said:Keep the original post as written when you update it, and add the correction underneath.
This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
That is the short version; the long version is somebody else's post.